| iNOS expression# |
| Characteristic, n (%) |
Group 1 |
Group 2 |
Group 3 |
Group 4 |
Total |
P-value* |
| Study population |
59 (36.4%) |
47(29.0%) |
21 (13.0%) |
35 (21.6%) |
162 (100%) |
|
| Modified Astler-Coller stage |
|
|
|
|
|
0.018 |
| A or B |
25 (30.5%) |
27 (32.7%) |
16 (19.5%) |
14 (17.1%) |
82 (100%) |
|
| C |
29 (46.0%) |
17 (27.0%) |
4 (6.3%) |
13 (20.6%) |
63 (100%) |
|
| D |
5 (29.4%) |
3 (17.6%) |
1 (5.9%) |
8 (47.1%) |
17 (100%) |
|
| T status |
|
|
|
|
|
0.005 |
| pT1 or pT2 |
8 (24.2%) |
13 (39.4%) |
9 (27.3%) |
3 (9.1%) |
33 (100%) |
|
| pT3 or pT4 |
51 (39.5%) |
34 (26.4%) |
12 (9.3%) |
32 (24.8%) |
129 (100%) |
|
|
| *Chi-square test. # Group 1 (low in cancer cells and macrophages), group 2 (low
in cancer cells and high in macrophages), group 3 (high in cancer cells and low in
macrophages), group 4 (high in cancer cells and macrophages). |
| Table 2: iNOS expression patterns and pathological parameters. |
